The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: A double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate
✍ Scribed by Rosa L. Drijgers; Frans R.J. Verhey; Gerrit Tissingh; Peter H.M.F. van Domburg; Pauline Aalten; Albert F.G. Leentjens
- Book ID
- 119304582
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 191 KB
- Volume
- 320
- Category
- Article
- ISSN
- 0022-510X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to
## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef
## Abstract Based on several open‐label and case studies, repetitive transcranial magnetic stimulation (rTMS) seems to have an antidepressive effect on patients with Parkinson's disease (PD). However, this hypothesis requires further confirmation. We conducted a randomized, double‐blind placebo‐con